Breakthrough for AlzeCure in the development of drugs for nerve pain
AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.
New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.
– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.
AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.
Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science
Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund (ERDF) and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.
BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development
As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.
Sally Sow and Turn UP: Winners of the Flemingsberg Science Award IDEA 2024
The music world can be a challenging place, both for organizers trying to reach their audience and for music lovers searching for events that suit their taste. Sally Sow, the winner of the Flemingsberg Science Award IDEA 2024, has developed Turn Up, a platform that simplifies organizing, discovering, and participating in local music events. With a focus on inclusion and accessibility, she aims to create a music scene where everyone feels welcome.
KTH’s Technical Preparatory Year Moves to Flemingsberg – Student Numbers Expected to Double in Autumn 2025
In the autumn of 2025, KTH will relocate its Technical Preparatory Year spots from Södertälje to Flemingsberg, resulting in a significant increase in student numbers at Campus Flemingsberg. By nearly doubling available seats and introducing a new learning center model in collaboration with 3 municipalities, KTH aims to meet the growing demand for technical education in the region.
